Lyell Immunopharma (LYEL) Competitors $9.41 -0.02 (-0.16%) As of 07/3/2025 03:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LYEL vs. RLAY, MRVI, TSHA, OPT, TYRA, DNA, KURA, MNMD, MGTX, and BCAXShould you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include Relay Therapeutics (RLAY), Maravai LifeSciences (MRVI), Taysha Gene Therapies (TSHA), Opthea (OPT), Tyra Biosciences (TYRA), Ginkgo Bioworks (DNA), Kura Oncology (KURA), Mind Medicine (MindMed) (MNMD), MeiraGTx (MGTX), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry. Lyell Immunopharma vs. Its Competitors Relay Therapeutics Maravai LifeSciences Taysha Gene Therapies Opthea Tyra Biosciences Ginkgo Bioworks Kura Oncology Mind Medicine (MindMed) MeiraGTx Bicara Therapeutics Lyell Immunopharma (NASDAQ:LYEL) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership. Do institutionals & insiders hold more shares of LYEL or RLAY? 66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 22.3% of Lyell Immunopharma shares are owned by company insiders. Comparatively, 4.9% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, LYEL or RLAY? Relay Therapeutics has higher revenue and earnings than Lyell Immunopharma. Relay Therapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyell Immunopharma$65K2,144.88-$342.99M-$25.00-0.38Relay Therapeutics$10.01M62.00-$337.71M-$2.23-1.62 Does the media favor LYEL or RLAY? In the previous week, Lyell Immunopharma's average media sentiment score of 0.00 equaled Relay Therapeutics'average media sentiment score. Company Overall Sentiment Lyell Immunopharma Neutral Relay Therapeutics Neutral Which has more risk and volatility, LYEL or RLAY? Lyell Immunopharma has a beta of -0.24, indicating that its stock price is 124% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Do analysts rate LYEL or RLAY? Lyell Immunopharma currently has a consensus target price of $15.00, indicating a potential upside of 59.32%. Relay Therapeutics has a consensus target price of $17.67, indicating a potential upside of 388.03%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relay Therapeutics is more favorable than Lyell Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Relay Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.83 Is LYEL or RLAY more profitable? Relay Therapeutics has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -514,649.22%. Relay Therapeutics' return on equity of -44.17% beat Lyell Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Lyell Immunopharma-514,649.22% -73.66% -60.99% Relay Therapeutics N/A -44.17%-39.53% SummaryRelay Therapeutics beats Lyell Immunopharma on 11 of the 14 factors compared between the two stocks. Get Lyell Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LYEL vs. The Competition Export to ExcelMetricLyell ImmunopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$139.42M$2.42B$5.50B$9.02BDividend YieldN/A1.77%5.38%4.10%P/E Ratio-0.389.1027.6020.30Price / Sales2,144.88490.15369.54104.24Price / CashN/A157.0736.6357.47Price / Book0.364.638.055.68Net Income-$342.99M$31.34M$3.18B$249.13M7 Day Performance5.31%3.25%2.82%3.30%1 Month Performance-30.10%6.80%3.69%5.20%1 Year Performance-68.82%1.89%35.41%21.37% Lyell Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LYELLyell Immunopharma2.7929 of 5 stars$9.42-0.2%$15.00+59.3%-68.8%$139.42M$65K-0.38270RLAYRelay Therapeutics2.1602 of 5 stars$3.25+0.5%$17.67+444.4%-42.3%$554.64M$10.01M-1.45330MRVIMaravai LifeSciences3.3748 of 5 stars$2.13+0.7%$6.64+212.4%-60.4%$543.70M$241.86M-1.87610TSHATaysha Gene Therapies3.3898 of 5 stars$2.49-0.2%$7.57+204.7%+11.6%$533.43M$8.33M-7.31180Analyst ForecastOPTOpthea0.5612 of 5 stars$3.41+7.2%$1.33-60.9%+80.4%$524.83M$120K0.008News CoverageGap UpTYRATyra Biosciences1.8354 of 5 stars$9.89+1.8%$30.83+211.9%-41.1%$524.05MN/A-6.0620Analyst ForecastDNAGinkgo Bioworks1.0334 of 5 stars$8.95+4.9%$5.77-35.6%N/A$522.73M$227.04M-0.98640Gap UpKURAKura Oncology4.5467 of 5 stars$5.93+0.9%$24.50+313.5%-70.5%$511.11M$53.88M-2.81130Gap UpMNMDMind Medicine (MindMed)3.1145 of 5 stars$6.74+1.4%$25.50+278.2%+0.8%$510.34MN/A-5.2440Positive NewsMGTXMeiraGTx4.4039 of 5 stars$6.33+0.3%$24.00+279.4%+86.7%$506.67M$33.28M-2.72300News CoverageBCAXBicara Therapeutics1.4349 of 5 stars$9.30+1.3%$31.86+242.6%N/A$504.13MN/A0.0032 Related Companies and Tools Related Companies RLAY Alternatives MRVI Alternatives TSHA Alternatives OPT Alternatives TYRA Alternatives DNA Alternatives KURA Alternatives MNMD Alternatives MGTX Alternatives BCAX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LYEL) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
